Hepatocellular carcinoma (HCC) exhibits profound heterogeneity at genetic, epigenetic, phenotypic and microenvironmental levels. Inter-patient heterogeneity reflects diverse aetiologies, including ...
Plasma TP53 as an indicator of poor survival in neoadjuvant-treated triple negative breast cancer: A prospective study and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast. This is an ASCO Meeting Abstract from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results